263 related articles for article (PubMed ID: 37031434)
1. Cancer immune escape: the role of antigen presentation machinery.
Kallingal A; Olszewski M; Maciejewska N; Brankiewicz W; Baginski M
J Cancer Res Clin Oncol; 2023 Aug; 149(10):8131-8141. PubMed ID: 37031434
[TBL] [Abstract][Full Text] [Related]
2. Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy.
de Charette M; Houot R
Haematologica; 2018 Aug; 103(8):1256-1268. PubMed ID: 30006449
[TBL] [Abstract][Full Text] [Related]
3. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
Dhatchinamoorthy K; Colbert JD; Rock KL
Front Immunol; 2021; 12():636568. PubMed ID: 33767702
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
[TBL] [Abstract][Full Text] [Related]
6. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion.
Jhunjhunwala S; Hammer C; Delamarre L
Nat Rev Cancer; 2021 May; 21(5):298-312. PubMed ID: 33750922
[TBL] [Abstract][Full Text] [Related]
7. Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy.
Cerezo-Wallis D; Soengas MS
Curr Pharm Des; 2016; 22(41):6234-6250. PubMed ID: 27568731
[TBL] [Abstract][Full Text] [Related]
8. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects.
Wu X; Li T; Jiang R; Yang X; Guo H; Yang R
Mol Cancer; 2023 Dec; 22(1):194. PubMed ID: 38041084
[TBL] [Abstract][Full Text] [Related]
9. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer.
Demel UM; Böger M; Yousefian S; Grunert C; Zhang L; Hotz PW; Gottschlich A; Köse H; Isaakidis K; Vonficht D; Grünschläger F; Rohleder E; Wagner K; Dönig J; Igl V; Brzezicha B; Baumgartner F; Habringer S; Löber J; Chapuy B; Weidinger C; Kobold S; Haas S; Busse AB; Müller S; Wirth M; Schick M; Keller U
J Clin Invest; 2022 May; 132(9):. PubMed ID: 35499080
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
11. Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy.
D'Amico S; Tempora P; Melaiu O; Lucarini V; Cifaldi L; Locatelli F; Fruci D
Front Immunol; 2022; 13():948297. PubMed ID: 35936007
[TBL] [Abstract][Full Text] [Related]
12. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.
Maggs L; Sadagopan A; Moghaddam AS; Ferrone S
Trends Cancer; 2021 Dec; 7(12):1089-1101. PubMed ID: 34489208
[TBL] [Abstract][Full Text] [Related]
13. The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer.
Kraemer AI; Chong C; Huber F; Pak H; Stevenson BJ; Müller M; Michaux J; Altimiras ER; Rusakiewicz S; Simó-Riudalbas L; Planet E; Wiznerowicz M; Dagher J; Trono D; Coukos G; Tissot S; Bassani-Sternberg M
Nat Cancer; 2023 May; 4(5):608-628. PubMed ID: 37127787
[TBL] [Abstract][Full Text] [Related]
14. [Diverse Molecular Mechanisms for Immune Evasion in Gastrointestinal Cancer].
Shibata T
Gan To Kagaku Ryoho; 2022 Mar; 49(3):243-247. PubMed ID: 35299174
[TBL] [Abstract][Full Text] [Related]
15. [Development of novel immunotherapy targeting cancer immune evasion].
Tamada K
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
[TBL] [Abstract][Full Text] [Related]
16. The significance of targeting lysosomes in cancer immunotherapy.
Xu Y; Shao B; Zhang Y
Front Immunol; 2024; 15():1308070. PubMed ID: 38370407
[TBL] [Abstract][Full Text] [Related]
17. The urgent need to recover MHC class I in cancers for effective immunotherapy.
Garrido F; Aptsiauri N; Doorduijn EM; Garcia Lora AM; van Hall T
Curr Opin Immunol; 2016 Apr; 39():44-51. PubMed ID: 26796069
[TBL] [Abstract][Full Text] [Related]
18. Exploiting Autophagy-Dependent Neoantigen Presentation in Tumor Microenvironment.
Koustas E; Trifylli EM; Sarantis P; Papadopoulos N; Papanikolopoulos K; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Matthaios D; Karamouzis MV
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833401
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance.
Balasubramanian A; John T; Asselin-Labat ML
Biochem Soc Trans; 2022 Apr; 50(2):825-837. PubMed ID: 35343573
[TBL] [Abstract][Full Text] [Related]
20. MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation.
Fang Y; Wang L; Wan C; Sun Y; Van der Jeught K; Zhou Z; Dong T; So KM; Yu T; Li Y; Eyvani H; Colter AB; Dong E; Cao S; Wang J; Schneider BP; Sandusky GE; Liu Y; Zhang C; Lu X; Zhang X
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 32990678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
